1-20 of 164
Wei Xu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Study of TT-01488, a Novel, Non-Covalent, Reversible BTK Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Yufu Li, Wei Xu, Caixia Li, Pengcheng He, Wei Yang, Xiangmin Tong, Ying Wang, Hongchan Zhang, Caixia Sun, Zejuan Sheng, Jean Fan, Jianyong Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 3036.
https://doi.org/10.1182/blood-2024-202976
Published: 2024
Journal Articles

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Yuqin Song, Qingqing Cai, Keshu Zhou, Ming Jiang, Zhengming Jin, Lei Zhang, Xiuhua Sun, Haiyan Yang, Lanfang Li, Kaiyang Ding, Junyuan Qi, Hongmei Jing, Wei Yang, Min Zhou, Jun Ma, Zhigang Peng, Wei Xu, Hui Zhou, Li Yu, Yuankai Shi, Guohui Cui, Zheng Wang, Nawei Liu, Yejiang Lou, Yue Shen, Yi Chen, Fenlai Tan, Jun Zhu
Journal: Blood
Blood (2024) 144 (Supplement 1): 3119.
https://doi.org/10.1182/blood-2024-194561
Published: 2024
Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Huayuan Zhu, Yi Miao, Shuchao Qin, Ming Liu, Yi Xia, Luomengjia Dai, Tonglu Qiu, Chong-Yang Ding, Hairong Qiu, Chun Qiao, Yujie Wu, Fei Li, Xiao Lu, Wei Xu, Lei Fan, Jianyong Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 3244.
https://doi.org/10.1182/blood-2024-204881
Published: 2024
Journal Articles

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Yuqin Song, Qingqing Cai, Keshu Zhou, Ming Jiang, Zhengming Jin, Lei Zhang, Xiuhua Sun, Haiyan Yang, Lanfang Li, Kaiyang Ding, Junyuan Qi, Hongmei Jing, Wei Yang, Min Zhou, Jun Ma, Zhigang Peng, Wei Xu, Hui Zhou, Li Yu, Yuankai Shi, Guohui Cui, Zheng Wang, Nawei Liu, Yejiang Lou, Yue Shen, Yi Chen, Fenlai Tan, Jun Zhu
Journal: Blood
Blood (2024) 144 (Supplement 1): 1635.
https://doi.org/10.1182/blood-2024-194572
Published: 2024
Journal Articles

Serum Tsrna Can be Used As a Biomarker of the Activation States of T Cells for Early Detection of GvHD after Allogeneic Stem Cell Transplantation

Lin Xia, Wei Xu, Shuhan Tang, Han Yao, Lu Zhao, Yuqing Liu, Ting Chen, Jie Tang, Xiaoli Chen, Li Wang, Shijie Yang, Yimei Feng, Xi Zhang
Journal: Blood
Blood (2024) 144 (Supplement 1): 7107.
https://doi.org/10.1182/blood-2024-204395
Published: 2024
Journal Articles

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

Jan Eckmann, Tanja Fauti, Marlene Biehl, Aintzane Zabaleta, Laura Blanco, Iva Lelios, Stefan Gottwald, Richard Rae, Stefanie Lechner, Christa Bayer, Quincy Dekempe, Franz Osl, Nadège Carrié, Sahar Kassem, Stefan Lorenz, Tony Christopeit, Alejandro Carpy, Alexander Bujotzek, Ann-Marie E. Bröske, Iryna Dekhtiarenko, Jan Attig, Leo Kunz, Floriana Cremasco, Roberto Adelfio, Georg Fertig, Stefan Dengl, Christian Gassner, Felix Bormann, Claudia Kirstenpfad, Thomas Emanuel Kraft, Sarah Diggelmann, Melanie Knobloch, Carina Hage, Romi Feddersen, Gordon Heidkamp, Thomas Pöschinger, Maud Lea Mayoux, Luise Bernasconi, Charles Dumontet, Felipe Prosper, Ludovic Martinet, Stephane Leclair, Wei Xu, Bruno Paiva, Christian Klein, Pablo Umaña
Journal: Blood
Blood blood.2024025987.
https://doi.org/10.1182/blood.2024025987
Published: 2024
Includes: Supplemental data
Journal Articles

A Single Center Real World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Leukeima/Small Lymphocytic Lymphoma

Huayuan Zhu, Luomengjia Dai, Yeqin Sha, Xiao Lu, Siqi Qian, Tonglu Qiu, Yi Miao, Yi Xia, Shuchao Qin, Ziyuan Zhou, Wei Wu, Lei Fan, Wei Xu, Jianyong Li
Journal: Blood
Blood (2023) 142 (Supplement 1): 4653.
https://doi.org/10.1182/blood-2023-189681
Published: 2023
Journal Articles

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

Yuqin Song, Keshu Zhou, Dengju Li, Jianda Hu, Dehui Zou, Sujun Gao, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Ru Feng, Jie Jin, Fangfang Lyu, Cheng Fang, Sheng Xu, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 1682.
https://doi.org/10.1182/blood-2023-181352
Published: 2023
Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Huayuan Zhu, Yi Miao, Yi Xia, Shuchao Qin, Wei Wu, Tonglu Qiu, Chong-Yang Ding, Hairong Qiu, Chun Qiao, Yujie Wu, Fei Li, Wei Xu, Jianyong Li
Journal: Blood
Blood (2023) 142 (Supplement 1): 4642.
https://doi.org/10.1182/blood-2023-188925
Published: 2023
Journal Articles

A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study

Yuqin Song, Qingqing Cai, Ming Jiang, Keshu Zhou, Lei Zhang, Xiuhua Sun, Zhengming Jin, Lanfang Li, Hongmei Jing, Zhigang Peng, Haiyan Yang, Junyuan Qi, Hui Zhou, Wei Yang, Min Zhou, Chunyan Ji, Wei Xu, Kaiyang Ding, Li Yu, Zheng Wang, Nawei Liu, Yejiang Lou, Yue Shen, Yi Chen, Fenlai Tan, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 4400.
https://doi.org/10.1182/blood-2023-180485
Published: 2023
Journal Articles

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Yuqin Song, Qingqing Cai, Ming Jiang, Keshu Zhou, Lei Zhang, Xiuhua Sun, Zhengming Jin, Lanfang Li, Hongmei Jing, Zhigang Peng, Haiyan Yang, Junyuan Qi, Hui Zhou, Wei Yang, Min Zhou, Chunyan Ji, Wei Xu, Kaiyang Ding, Li Yu, Zheng Wang, Nawei Liu, Yejiang Lou, Yue Shen, Yi Chen, Fenlai Tan, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3033.
https://doi.org/10.1182/blood-2023-180694
Published: 2023
Journal Articles

Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma

Jie Zha, Qinwei Chen, Wei Zhang, Hongmei Jing, Jingjing Ye, Haifeng Yu, Shuhua Yi, Caixia Li, Zhong Zheng, Wei Xu, Zhifeng Li, Lingyan Ping, Xiaohua He, Liling Zhang, Ying Xie, Feili Chen, Xiuhua Sun, Liping Su, Huilai Zhang, Zhijuan Lin, Haiyan Yang, Weili Zhao, Lugui Qiu, Zhiming Li, Yuqin Song, Bing Xu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3048.
https://doi.org/10.1182/blood-2023-182812
Published: 2023
Journal Articles

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results

Xinxin Cao, Jie Jin, Fu Cheng Cheng, Shuhua Yi, Weili Zhao, Zimin Sun, Wei Yang, Dengju Li, Guohui CUI, Jianda Hu, Ting Liu, Yongping Song, Bing Xu, Zunmin Zhu, Wei Xu, Mingzhi Zhang, Sichen Li, Weige Wang, Renbin Zhao, Daobin Zhou
Journal: Blood
Blood (2023) 142 (Supplement 1): 3039.
https://doi.org/10.1182/blood-2023-181500
Published: 2023
Journal Articles

A Real-World Study of Zanubrutinib Treatment in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Huayuan Zhu, Yi Xia, Yi Miao, Shuchao Qin, Wei Wu, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li
Journal: Blood
Blood (2023) 142 (Supplement 1): 6554.
https://doi.org/10.1182/blood-2023-189110
Published: 2023
Journal Articles

Integrating Multi-Omics to Reveal the Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Rui Jiang, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Hui Jin, Jianyong Li
Journal: Blood
Blood (2022) 140 (Supplement 1): 6985–6987.
https://doi.org/10.1182/blood-2022-169720
Published: 2022
Journal Articles

Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li
Journal: Blood
Blood (2022) 140 (Supplement 1): 4117–4118.
https://doi.org/10.1182/blood-2022-170985
Published: 2022
Journal Articles

Clinical Characteristics and Outcomes of Follicular Lymphoma Patients with Extranodal Involvement: Analysis of a Series of 1090 Cases in China

Zhijuan Lin, Jie Zha, Shuhua Yi, Zhifeng Li, Lingyan Ping, Xiaohua He, Liyuan Fan, Haifeng Yu, Zhong Zheng, Wei Xu, Feili Chen, Ying Xie, Bi-yun Chen, Huilai Zhang, Li Wang, Kaiyang Ding, Wenyu Li, Haiyan Yang, Weili Zhao, Lugui Qiu, Zhiming LI, Yuqin Song, Bing Xu
Journal: Blood
Blood (2022) 140 (Supplement 1): 11979–11980.
https://doi.org/10.1182/blood-2022-162488
Published: 2022
Journal Articles

Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis

Yuqin Song, Keshu Zhou, Dehui Zou, Dengju Li, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Daobin Zhou, Constantine S. Tam, David Simpson, Michael L. Wang, Tycel J. Phillips, Stephen Opat, Cheng Fang, Shaohui Sun, Jun Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 6501–6503.
https://doi.org/10.1182/blood-2022-162135
Published: 2022
Journal Articles

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Hui Shen, Jingyan Qiu, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li
Journal: Blood
Blood (2022) 140 (Supplement 1): 4164–4165.
https://doi.org/10.1182/blood-2022-170815
Published: 2022
Journal Articles

Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide (CPCT) for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Multicenter Phase II Trial

Wei Xu, Jin-Hua Liang, Li Wang, Xiao-Dong Wang, Guohui Cui, Jianfeng Zhou, Jingyan Xu, Luqun Wang, Rong Liang, Bi-yun Chen, Jian Cheng, Jian-Yong Li
Journal: Blood
Blood (2022) 140 (Supplement 1): 9484–9486.
https://doi.org/10.1182/blood-2022-157014
Published: 2022